Kiniksa Pharmaceuticals International (NASDAQ:KNSA) COO Sells $500,714.88 in Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) COO Eben Tessari sold 12,048 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $41.56, for a total transaction of $500,714.88. Following the transaction, the chief operating officer directly owned 16,666 shares in the company, valued at $692,638.96. This represents a 41.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Eben Tessari also recently made the following trade(s):

• On Wednesday, November 26th, Eben Tessari sold 200 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $42.89, for a total value of $8,578.00.
• On Monday, November 17th, Eben Tessari sold 12,470 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $41.24, for a total value of $514,262.80.
• On Tuesday, October 14th, Eben Tessari sold 12,368 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $37.67, for a total value of $465,902.56.
• On Monday, September 29th, Eben Tessari sold 42,000 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $38.33, for a total value of $1,609,860.00.

Kiniksa Pharmaceuticals International Stock Performance

KNSA opened at $43.19 on Friday. Kiniksa Pharmaceuticals International, plc has a 52-week low of $17.82 and a 52-week high of $43.73. The firm has a market cap of $3.27 billion, a P/E ratio of 95.98 and a beta of 0.02. The business’s fifty day moving average is $40.21 and its 200-day moving average is $34.94.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, October 28th. The company reported $0.23 earnings per share for the quarter, missing the consensus estimate of $0.31 by ($0.08). The firm had revenue of $180.86 million for the quarter, compared to the consensus estimate of $166.64 million. Kiniksa Pharmaceuticals International had a return on equity of 7.46% and a net margin of 6.01%.The company’s revenue for the quarter was up 61.2% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.18) EPS. On average, research analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. EverSource Wealth Advisors LLC raised its position in Kiniksa Pharmaceuticals International by 140.4% in the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after purchasing an additional 532 shares during the last quarter. Osaic Holdings Inc. acquired a new position in shares of Kiniksa Pharmaceuticals International in the second quarter valued at approximately $31,000. USA Financial Formulas bought a new position in Kiniksa Pharmaceuticals International in the 3rd quarter valued at approximately $32,000. US Bancorp DE bought a new position in Kiniksa Pharmaceuticals International in the 1st quarter valued at approximately $33,000. Finally, Quantbot Technologies LP acquired a new stake in Kiniksa Pharmaceuticals International during the 2nd quarter worth approximately $43,000. Institutional investors own 53.95% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Citigroup boosted their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, October 17th. Wedbush reiterated an “outperform” rating and issued a $48.00 price target on shares of Kiniksa Pharmaceuticals International in a research note on Tuesday, December 2nd. TD Cowen initiated coverage on Kiniksa Pharmaceuticals International in a report on Monday, September 29th. They set a “buy” rating and a $60.00 price target for the company. Zacks Research lowered Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Finally, Wall Street Zen cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 2nd. Six analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, Kiniksa Pharmaceuticals International has an average rating of “Moderate Buy” and a consensus price target of $52.00.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.